Page last updated: 2024-08-21

quinazolines and Pancreatic Neoplasms

quinazolines has been researched along with Pancreatic Neoplasms in 324 studies

Research

Studies (324)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.31)	18.7374
1990's	3 (0.93)	18.2507
2000's	119 (36.73)	29.6817
2010's	190 (58.64)	24.3611
2020's	11 (3.40)	2.80

Authors

Authors	Studies
Akahoshi, K; Ban, D; Ishikawa, Y; Kudo, A; Murase, Y; Ogawa, K; Ono, H; Tanabe, M; Tanaka, S; Ueda, H; Yoshioka, R	1
Gammon, ST; Muzzioli, R; Pisaneschi, F; Piwnica-Worms, D; Radaram, B; Sutton, MN; Yang, P	1
Frankel, TL; Green, MD; Jiang, L; Karnak, D; Lawrence, TS; Lima, F; McMillan, MT; Morgan, MA; Parsels, JD; Parsels, LA; Wang, W; Wang, Z; Zhang, Q; Zhao, X	1
Fang, H; He, H; Li, Y; Liu, Y; Xu, J; Zhang, S; Zhang, Y	1
Kawada, M; Ohishi, T; Tatsuda, D; Yoshida, J	1
Ko, AH	1
Alimoghaddam, K; Alishahi, Z; Esmaeili, F; Eyvani, H; Ghaffari, P; Ghaffari, SH; Ghavamzadeh, A; Momeny, M; Tavakkoly-Bazzaz, J; Zaghal, A	1
Booth, L; Dent, P; Hancock, JF; Hoff, DV; Poklepovic, A	1
Chen, H; Hong, Z; Jamshed, MB; Liao, Y; Tong, H; Wang, J; Wang, Z; Zhang, Q; Zheng, P; Zhou, B	1
Kaushik, AC; Wang, X; Wang, YJ; Wei, DQ	1
Cardin, DB; Glazer, PM; Grossman, SR; Ivy, SP; Kato, S; Kim, JW; LoRusso, PM; Shyr, Y; Vaishampayan, UN	1
Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T	1
Anastasov, N; Atkinson, MJ; Kell, R; Moertl, S; Payer, S; Winkler, K	1
Damen, E; Ehlert, JE; Feger, D; Heidemann-Dinger, C; Kubbutat, M; Leenders, R; Lenstra, DC; Mecinović, J; Müller, D; Müller, G; Schächtele, C; Trivarelli, F; van Bree, B; van de Sande, M; Wegert, A; Zijlmans, R	1
Boeck, S; Egg, R; Goritschan, C; Haas, M; Heinemann, V; Jung, A; Kirchner, T; Laubender, RP; Modest, DP; Neumann, J; Ormanns, S	1
Adair, SJ; Bauer, TW; Borgman, CA; Chopivsky, ME; Cowan, CR; Gilmer, TM; Lindberg, JM; Lowrey, BT; Newhook, TE; Parsons, JT; Stelow, EB; Stokes, JB; Walters, DM	1
Chen, JZ; Di, MY; Ding, H; Huang, YF; Mao, C; Tang, JL; Wu, XY; Yang, ZY; Yuan, JQ; Zheng, DY	1
Kim, R; Kothari, N; Saif, MW	1
Okamoto, T; Onda, S	1
Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C	1
Hejduk, K; Pochop, L	1
Abbruzzese, JL; Carlson, P; Fogelman, DR; George, B; Javle, M; Khalil, MA; Overman, M; Qiao, W; Varadhachary, G; Wolff, RA	1
Duffy, A; Greten, TF; Liewehr, DJ; Rahma, OE; Steinberg, SM	1
Carson, DD; Engel, BJ	1
Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L	1
Bartsch, R; Chrysikos, D; Dimopoulos, MA; Filipits, M; Papadimitriou, CA; Sergentanis, TN; Zagouri, F; Zografos, CG	1
He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y	1
Ogbonna, OH; Saif, MW	1
Huber, KE; Saif, MW; Savir, G	1
Ramfidis, VS; Saif, MW; Syrigos, KN	1
Ohkawa, S; Sakamoto, Y; Ueno, M	1
Bria, E; Cognetti, F; Gamucci, T; Gelibter, A; Mansueto, G; Milella, M; Moscetti, L; Ruggeri, EM; Sperduti, I; Vaccaro, V	1
Che, J; Shen, XJ; Sun, KK; Wu, XY; Yang, D; Zhao, H; Zhong, N	1
Amano, R; Hirakawa, K; Hirata, K; Kimura, K; Komoto, M; Murata, A; Nakata, B	1
Azzariti, A; Brunetti, AE; Gnoni, A; Lorusso, V; Maiello, E; Merchionne, F; Nardulli, P; Reni, M; Santini, D; Silvestris, N; Tonini, G; Vincenti, L	1
Cao, L; Freeman, JW; Hill, P; Nawrocki, ST; Peterson, L; Venkatasubbarao, K; Zhao, S; Zhou, Q	1
Aiba, K; Fujiwara, Y; Furukawa, K; Futagawa, Y; Kitamura, H; Misawa, T; Shiba, H; Tsutsui, N; Uwagawa, T; Yanaga, K	1
Blackford, AL; Cameron, JL; Choti, MA; Donehower, RC; Edil, BH; Fan, KY; Herman, JM; Hidalgo, M; Hruban, RH; Iacobuzio-Donahue, CA; Laheru, DA; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD	1
Bahra, M; Ehemann, V; Endris, V; Goeppert, B; Kamphues, C; Klauschen, F; Lorenz, K; Muckenhuber, A; Neuhaus, P; Sinn, B; Stenzinger, A; Warth, A; Weichert, W	1
Deitz, S; Gore, J; Korc, M; Ouyang, H	1
Fujii, T; Fujiwara, M; Fukuda, S; Hotta, Y; Kanda, M; Kasuya, H; Kobayashi, D; Kodera, Y; Koike, M; Nakayama, G; Nomoto, S; Sahin, TT; Sugimoto, H; Tan, G; Tanaka, C; Tanaka, M; Tsurumaru, N; Yamada, S; Yamamura, K	1
Bansal, R; Blackburn, C; Brown, L; Colombo, R; Gasaway, R; Gore, J; Grimes, BR; Herbert, BS; Jeong, J; Korc, M; March, KL; Slee, RB; Victorino, J	1
Byagowi, S; Darabi, M; Fayezi, S; Mirshahvaladi, S; Sahmani, M	1
Furuse, J	1
Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M	1
Egawa, C; Kagawa, Y; Kato, T; Katsura, Y; Nakahira, S; Okishiro, M; Sakisaka, H; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H	1
Aust, D; Buchholz, M; Gress, T; Griesmann, H; Krug, S; Kühnemuth, B; Lölkes, C; Michl, P; Milosevic, N; Mühlberg, L; Pilarsky, C; Ripka, S	1
Alcolea, V; Aparicio, J; Corbellas, M; Diaz Beveridge, R; Fonfría, M; García, J; Giménez, A; Montalar, J; Segura, Á	1
Chan, EH; Chan, SL; Chan, ST; He, ZX	1
Chen, M; Huang, H; Wang, C; Xie, J; Yang, A; Yin, Q; Zhang, B	1
Chiba, T; Kanai, M; Kawaguchi, Y; Kodama, Y; Matsumoto, S; Mori, Y; Nishimura, T; Takaori, K; Uemoto, S; Uza, N; Xue, P	1
Edling, CE; Falasca, M; Ghonaim, R; Maffucci, T; Selvaggi, F	1
Berlin, J; Cardin, DB; Chan, E; DeVore, R; Goff, L; Grigorieva, J; Holloway, M; Li, CI; McClanahan, P; Meyer, K; Schlabach, L; Shyr, Y; Winkler, C	1
Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Watkins, DJ; Webb, J	1
Cao, Z; Li, H; Li, J; Li, M; Lu, Z; Shu, H; Wang, T; Xu, J; Yang, J; You, L; Zhang, T; Zhao, Y; Zhou, L	1
Geissler, M; Steins, M; Thomas, M	2
Anderson, E; Bahary, N; Charpentier, K; Clark, A; Kennedy, T; Lopez, CD; McNulty, B; Miner, T; Safran, H; Schumacher, A; Shipley, J; Sio, T; Sun, W; Vakharia, J; Whiting, S	1
Bridgewater, J; Davidenko, I; Ducreux, M; Fittipaldo, A; Hillenbach, C; Klughammer, B; Kupcinskas, L; Propper, D	1
Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G	1
Bartosiewicz, M; Boeck, S; Haas, M; Heinemann, V; Isaacson, J; Kirchner, T; Kleespies, A; Kruger, S; Laubender, RP; Mann, E; Ormanns, S; Raponi, M	1
Au, HJ; Chen, E; Dhani, N; Gill, S; Hedley, D; Kamel-Reid, S; Moore, MJ; Renouf, DJ; Tang, PA; Tran-Thanh, D; Tsao, MS; Wang, L	1
Baxter, RC; Gill, AJ; Hugh, TJ; Julovi, SM; Pavlakis, N; Peters, L; Samra, JS; Smith, RC; Wong, MH; Xue, A	1
Belani, CP; Gusani, N; Jiang, Y; Kaifi, J; Kimchi, ET; Mackley, HB; Staveley-O'Carroll, KF; Zhu, J	1
Christopoulou, A; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katopodis, O; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Polyzos, A; Souglakos, J; Stathopoulos, E	1
Alejandre, MJ; Aránega, A; Caba, O; Delgado, JR; Iglesias, J; Irigoyen, A; Linares, A; Martin, M; Ortuño, FM; Palomino, RJ; Perales, S; Prados, JC; Rojas, I; Torres, C	1
Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY	1
Benedetti, JK; Blanke, CD; Gaur, R; Goldman, B; Iqbal, S; Lenz, HJ; Lowy, AM; Philip, PA; Ramanathan, RK; Wakatsuki, T; Whitehead, RP	1
Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN	1
Cheung, TT; Chiu, JW; Fan, ST; Leung, R; Pang, R; Poon, R; Wong, H; Yau, T	1
Fuereder, T; Hoeflmayer, D; Kornek, G; Kuehrer, I; Scheithauer, W; Stift, J; Stranzl, N	1
Boeck, S; Clemens, MR; Esposito, I; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Greten, TF; Haas, M; Heinemann, V; Jung, A; Kirchner, T; Kruger, S; Laubender, RP; Märten, A; Ormanns, S; Schlitter, AM; Sipos, B; Siveke, JT; Vehling-Kaiser, U; Winkelmann, C	1
Annunziato, S; Benedicenti, F; Brasca, S; Calabria, A; Gallina, P; Montini, E; Naldini, L; Ranzani, M	1
Cai, W; Cheng, K; Li, T; Shao, T; Zhao, B; Zheng, Y	1
Aprile, G; Ciuleanu, T; Csutor, Z; Federowicz, I; Fittipaldo, A; Hsu, C; Klughammer, B; Li, CP; Lipp, R; Meng, X; Moore, M; Nowara, E; Stemmer, SM; Tham, CK; Van Cutsem, E; Van Laethem, JL; Zeaiter, A	1
Alagesan, B; Bardeesy, N; Benes, CH; Contino, G; Corcoran, RB; Deshpande, V; Engelman, J; Guimaraes, AR; Hezel, AF; Loda, M; Weissleder, R; Wojtkiewicz, GR; Wong, KK	1
Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR	1
Adaire, B; Cescon, TP; Choi, M; Cohen, SJ; Duncan, G; Hall, MJ; Joiner, M; Konski, A; McSpadden, E; Meropol, NJ; Meyer, JE; Philip, P; Shields, A	1
Graziani, C; Hegde, S; Saif, MW	1
He, X; Kong, Y; Li, W; Xiao, M; Zhang, H	1
Geng, L; Liu, Y; Wang, G; Wei, F; Zhang, P; Zhang, Y	1
Batra, SK; Ganti, AK; Haridas, D; Lakshmanan, I; Ponnusamy, MP; Rachagani, S; Seshacharyulu, P; Yan, Y	1
Buyse, M; Ding, K; Parulekar, WR; Péron, J; Roche, L; Roy, P	1
Bhattacharya, R; Bovonratwet, P; Liu, L; Mathew, MP; Saeui, CT; Tan, E; Yarema, KJ	1
Alves, F; Bellizzi, A; Bruns, P; Cardone, RA; Casavola, V; Greco, MR; Kalthoff, H; Menga, M; Pilarsky, C; Reshkin, SJ; Saccomano, M; Schwab, A; Zaccagnino, A; Zeeberg, K	1
Hu, HG; Huang, JJ; Shen, H; Zhao, J	1
Takahashi, M	1
Mazo, A; Pérez-Torras, S; Urtasun, N; Vidal-Pla, A	1
Aprile, G; Cardellino, GG; Foltran, L; Macerelli, M; Mazzer, M	1
Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH	1
Almeida, GM; Coelho, MA; Coelho, SC; Pereira, MC; Santos-Silva, F	1
Aasrum, M; Brusevold, IJ; Christoffersen, T; Sandnes, D; Tveteraas, IH; Ødegård, J	1
Biddick, L; Brewer, M; Devarkonda, V; Janakiram, NB; Lightfoot, S; Madka, V; Mohammed, A; Rao, CV; Steele, VE	1
Gabrielson, A; He, AR; Hwang, JJ; Ley, L; Marshall, JL; Pishvaian, MJ; Weiner, LM; Wu, Z; Zhuang, T	1
Amellal, N; Bahleda, R; Deutsch, E; Farace, F; Gazzah, A; Hollebecque, A; Marzin, K; Massard, C; Ould-Kaci, M; Roux, F; Soria, JC; Varga, A	1
Chen, YW; Cheng, KH; Hsiao, PJ; Hung, WC; Kuo, KK; Su, HT; Weng, CC; Wu, DC	1
Favaudon, V; Fernet, M; Giocanti, N; Huguet, F; Larsen, AK	1
Bradshaw-Pierce, EL; Eckhardt, SG; Eppers, S; Freas, E; Kane, MA; Kessler, ER; Leong, S; Lieu, CH; Messersmith, WA; Nallapreddy, S; O'byrant, CL; Pitts, TM; Spratlin, J; Weekes, C	1
Che, XF; Handa, H; Hiramoto, M; Itoi, T; Kazama, H; Kokuba, H; Miyazawa, K; Moriya, S; Mukai, S; Ōmura, S; Sakamoto, S; Sugawara, A; Sunazuka, T; Yokoyama, T	1
Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM; Solca, F	1
Bagadi, M; Binda, MM; Chaltin, P; Daniels, VW; Dehairs, J; Khan, NA; Marchand, A; Munck, S; Rueda-Rincon, N; Swinnen, JV; Talebi, A; Thimiri Govinda Raj, DB; Vanderhoydonc, F; Willemarck, N	1
Cheng, M; Conteh, AM; Craven, KE; Gore, J; Imasuen-Williams, IE; Korc, M	1
Campbell, F; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Evans, A; Falk, S; Ghaneh, P; Greenhalf, W; Hickish, T; Jackson, R; Madhusudan, S; Middleton, G; Neoptolemos, JP; Palmer, DH; Propper, D; Rawcliffe, C; Ross, P; Shaw, VE; Valle, JW; Wadd, N; Wadsley, J; Wasan, H	1
Saif, MW	3
Laurent-Puig, P; Taieb, J	1
Rocha-Lima, C; Vulfovich, M	1
Huo, L; Li, M; Liu, J; Liu, M; Yu, H; Zhou, J	1
Ahmad, A; Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH	1
Evans, TR; Kalofonos, HP; Koutras, AK; Makatsoris, T; Mastronikolis, NS; Papadeas, ES	1
Chirinos, RE; Falo, LD; Geskin, LJ; Pomerantz, RG	1
Alessio, M; Balsamo, M; Di Modugno, F; Gertler, FB; McConkey, DJ; Melucci, E; Milella, M; Mottolese, M; Natali, PG; Nisticò, P; Philippar, U; Pino, MS	1
Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L	1
Kollar, LE; Lawrence, TS; Maybaum, J; Morgan, MA; Normolle, DP; Parsels, LA	1
Bafaloukos, D; Bobos, M; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalogera-Fountzila, A; Kalogeras, KT; Karayannopoulou, G; Kosmidis, P; Koutras, AK; Linardou, H; Murray, S; Samantas, E; Xiros, N	1
Jing, DD; Lu, YY; Wang, XP; Wu, K; Xu, M	1
Boehm, KA; Cartwright, T; Richards, DA	1
Goggins, MG; Harsha, HC; Hidalgo, M; Hruban, RH; Jimeno, A; Kamath, U; Maitra, A; Mihalas, AB; Molina, H; Pandey, A; Schulick, RD	1
Cao, PJ; Dhani, N; Do, T; Hedley, DW; Hill, RP; Magalhaes, JM; Pham, NA; Schwock, J	1
Höhler, T; Oettle, H; Staib, L	1
Heinemann, V	1
Bergmann, F; Breinig, M; Ehemann, V; Esposito, I; Fischer, L; Friess, H; Herpel, E; Höpfner, M; Kern, MA; Kleeff, J; Köhler, C; Rieker, RJ; Schirmacher, P	1
Muslimov, GF	1
Brell, JM; Dranko, S; Evans, T; Kiefer, GJ; Lenzner, D; Matin, K; Ramanathan, RK; Rath, L; Schlesselman, JJ; Schmotzer, A; Volkin, RL	1
Bennouna, J; Cosaert, J; Gill, S; Humblet, Y; Moore, MJ; Scheithauer, W; Shang, A; Van Cutsem, E; Van Laethem, JL; Verslype, C; Vervenne, WL	1
Chen, H; Chen, Y; Eckhardt, SG; Kane, M; Leong, S; Mack, P; McCarter, MD; Olsen, CC; Raben, D; Schefter, TE; Stiegmann, G	1
Li, T; Perez-Soler, R	1
Chang, BW; Saif, MW	1
Kaley, K; Li, J; Peccerillo, J; Saif, MW	1
De Oliveira, E; Green, TP; Hidalgo, M; Jimeno, A; Messersmith, WA; Morgan, S; Rajeshkumar, NV; Tan, AC; Walker, J; Warren, MV; Womack, C; Wombwell, H	1
Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Sargent, M; Schafer, C; Seufferlein, T	1
Li, J; Saif, MW	1
Chen, F; Han, X; Lin, H; Sun, Y; Yong, W; Zheng, M; Zhou, X; Zhu, Y	1
Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, T; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Märten, A; Neugebauer, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C	1
Blum, H; Bruns, CJ; Camaj, P; De Toni, EN; Faktorova, D; Ischenko, I; Jauch, KW; Krebs, S; Seeliger, H	1
Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J	1
Georgieva, I; Grabowski, P; Holstein, J; Hopfenmüller, W; Koychev, D; Wang, Y; Zeitz, M	1
Amano, R; Hirakawa, K; Kawajiri, H; Komoto, M; Nakata, B; Nishii, T; Shinto, O; Yamada, N; Yashiro, M	1
Gnanaraj, J; Saif, MW	1
Ardavanis, A; Doufexis, D; Karagiannis, A; Kountourakis, P; Rigatos, G; Tzovaras, AA	1
Lai, JI; Lin, PC; Tzeng, CH; Wang, WS	1
Baerman, KM; Calvo, BF; Cox, AD; Kimple, RJ; Sartor, CI; Shields, JM; Tepper, JE; Vaseva, AV	1
Abbruzzese, JL; El-Rayes, BF; Ferris, AM; Hess, K; Javle, MM; Kaseb, AO; Philip, PA; Sarkar, FH; Shields, AF; Varadhachary, GR; Wolff, RA	1
Bergsland, EK; Dito, E; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Schillinger, B; Scott, J; Tempero, MA; Venook, AP	1
Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH; Schaffert, JM	1
Garber, K	1
Mehta, SP	1
Greten, TF; Manns, MP; Plentz, RR	1
Glimelius, B	1
Fietkau, R; Heinemann, V; Knoefel, WT; Oettle, H; Tannapfel, A	1
Chefrour, M; Ciccolini, J; Ferri-Dessens, RM; Fischel, JL; Formento, P; Francoual, M; Giacometti, S; Marouani, H; Mercier, C; Milano, G; Renée, N	1
Abbruzzese, JL; Davis, D; Fogelman, D; Javle, MM; Reddy, SA; Shroff, RT; Varadhachary, GA; Wolff, RA; Xiong, H; Zhang, Y	1
Arnoletti, JP; Frolov, A; Heslin, MJ; Howard, JH; Kossenkov, AV; Kulesza, P; Liles, JS; Tzeng, CW	1
Landgraf, R	1
Kaley, K; Penney, R; Saif, MW; Syrigos, K	1
Abu-Khalaf, M; Gunturu, KS; Saif, MW	1
Chiu, CW; Hanahan, D; Nozawa, H	1
Siu, LL	1
Chin, K; da Cunha Santos, G; Dhani, N; Kamel-Reid, S; Ludkovski, O; Moore, MJ; Parulekar, W; Squire, J; Tsao, MS; Tu, D	1
Bai, CM; Cheng, YJ; Zhang, ZJ	1
Barriuso, J; Belda-Iniesta, C; Borrega, P; Castro, J; Feliu, J; González-Barón, M; León, A; López, M; López-Gómez, L; Martínez, V	1
Clynes, M; McDermott, R; O'Connor, R; Sheikh, R; Walsh, N	1
Bodvarsdottir, SK; Eyfjord, JE; Ogmundsdottir, HM; Steingrimsdottir, G; Vidarsdottir, L	1
Abbruzzese, JL; Logsdon, CD	1
Crawford, H; Ely, M; Janakiram, NB; Li, Q; Lightfoot, S; Madka, V; Mohammed, A; Rao, CV; Steele, VE	1
Bahary, N; Bao, PQ; Bartlett, DL; Hughes, SJ; Krasinkas, A; Lee, KK; Lembersky, BC; Moser, AJ; Ramanathan, RK; Zeh, HJ	1
Holzman, DC	1
Daum, S; Epple, HJ; Grozdanovic, Z; Kunkel, J; Loddenkemper, C; Schmittel, A; Schulze, K; Zeitz, M	1
Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI	1
Chen, E; Gauthier, I; Gill, S; Goel, R; Hedley, D; Jonker, D; McIntosh, L; Moore, MJ; Renouf, DJ; Seymour, L; Southwood, B; Walde, D; Walsh, W	1
Boku, N; Funakoshi, A; Furuse, J; Iguchi, H; Ioka, T; Ito, T; Komatsu, Y; Nakachi, K; Nakagawa, K; Nakamori, S; Ohkawa, S; Okusaka, T; Yamao, K	1
Azzariti, A; Colucci, G; Fratto, ME; Galluzzo, S; Maiello, E; Santini, D; Silvestris, N; Tommasi, S; Tonini, G; Vincenzi, B; Zoccoli, A	1
Beham, A; Bodo, K; Lackner, K; Liegl, B; Martin, D; Tsybrovskyy, O	1
Egloff, AM; Grandis, JR	1
Merchant, NB; Nagaraj, NS; Washington, MK	1
Azzariti, A; Bocci, G; Chiarappa, P; Del Bufalo, D; Del Tacca, M; Fioravanti, A; Mangia, A; Paradiso, A; Porcelli, L; Quatrale, AE; Sebastian, S; Simone, GM; Sini, P	1
Mountzios, G; Syrigos, KN	1
Choudhary, A; Diep, CH; Han, H; Munoz, RM; Von Hoff, DD	1
Oberstein, PE; Saif, MW	1
Gu, FY; Hu, XY; Li, MD; Shen, H; Yuan, Y; Zhong, X	1
Bang, YJ; Kang, HJ; Kim, BS; Kim, JS; Lee, KH; Lee, KW; Oh, DY; Park, YS; Ryoo, HM; Sohn, CH; Song, HS; Zang, DY	1
Collisson, EA; Cooc, J; Danenberg, KL; Feiler, HS; Gibb, WJ; Gray, JW; Gu, S; Hanahan, D; Jakkula, L; Kim, GE; Ko, AH; Olshen, AB; Olson, P; Sadanandam, A; Spellman, PT; Tempero, MA; Truitt, M; Weinkle, J	1
Bigg, M; Della Zanna, G; Garcia, A; Gonzalez, R; Hewitt, SM; Imagawa, D; Lee, J; Lipkin, S; Meyskens, F; Richmond, E; Rodriguez, LM; Schnoll-Sussmans, F; Tucker, C; Wong, V; Zell, JA	1
Agrogiannis, G; Gamaletsou, MN; Kechagias, G; Papageorgiou, A; Syrios, J; Tsavaris, N; Xynos, ID	1
Adenis, A; Conroy, T; Gavoille, C	1
Balaraman, S; Ballouz, S; Boxwala, IG; Cotant, MB; Hardy-Carlson, M; Jaiyesimi, IA; Jury, RP; Margolis, J; Marvin, KS; Nadeau, L; Robertson, JM; Wallace, M; Ye, H	1
Gunn, JR; Korc, M; Sempere, LF	1
Balaraman, S; Gustafson, G; Huang, J; Jury, R; Khilanani, P; Margolis, J; McIntosh, B; Nadeau, L; Robertson, JM	1
Arnoletti, JP; Frolov, A; Frost, AR; Heslin, MJ; Kossenkov, AV; Kulesza, P; Liles, JS; Mikhaylina, A	1
Baek, KK; Choi, YL; Jang, HL; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lim, DH; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, JH	1
Cerny, T; De Dosso, S; Koeberle, D; Renggli, V; Saletti, P; Sessa, C	1
Dalgleish, AG; Guertler, U; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM; Solca, F	1
Li, DW; Liu, M; Luo, YG; Shi, XJ; Sun, XD; Sun, XO; Wu, XJ; Yao, CF; Yu, HY; Zhou, J	1
Huang, J; Margolis, J; Nadeau, L; Robertson, JM; Yan, D; Ye, H	1
Asmis, TR; Hilton, JF; Jonker, DJ; Moore, MJ; O'Callaghan, CJ; Parulekar, W; Powell, ED; Tu, D; Vickers, MM	1
Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH	1
Conradt, L; Diersch, S; Eser, S; Godl, K; Kleeff, J; Michalski, CW; Saur, D; Schaab, C; Schmid, RM; Schneider, G; Schnieke, A; Tebbe, A	1
Conroy, T; Mitry, E	1
Aranda, E; Arrivi, A; Díaz-Rubio, E; Galán, M; Irigoyen, A; Manzano, JL; Mendez, MJ; Pericay, C; Rivera, F; Safont, MJ; Sastre, J; Valladares-Ayerbes, M	1
Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M	1
Chen, H; Guo, HC; Lin, SZ; Liu, DL; Liu, HB; Ni, ZL; Tong, HF; Wang, ZH; Wei, WT	1
Chachoua, A; Cohen, DE; de Souza, A; Wnorowski, AM	1
Bazzan, AJ; Deshmukh, S; Levine, M; Littman, S; Mitchell, E; Monti, DA; Newberg, AB; Pillai, MV; Yeo, CJ; Zabrecky, G	1
Cha, YJ; Go, S; Hwang, IG; Jang, JS; Kang, JH; Kang, MH; Kwon, HC; Lee, GW; Lee, S; Oh, SY	1
Liu, BX; Ying, JE; Zhu, LM	1
Saif, MW; Strimpakos, AS; Syrigos, KN	1
Azria, D; Bascoul-Mollevi, C; Campigna, E; Chardès, T; Coelho, M; Gaborit, N; Larbouret, C; Mach, JP; Pèlegrin, A; Robert, B	1
Capasso, A; Ciardiello, F; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T	1
Aklilu, M; Bernard, SA; Blackstock, AW; Davies, JM; Goldberg, RM; Ivanova, A; O'Neil, BH; Raftery, L; Tepper, JE	1
Bahlo, M; Klapdor, R; Klapdor, S	1
Hong, TH; Jeon, EK; Ko, YH; Lee, IS; Lee, MA; Won, HS; You, YK	1
Houts, AC; Leon, L; Miller, PJ; Reyes, C; Satram-Hoang, S; Schwartzberg, LS; Stepanski, EJ; Walker, MS; Wojtowicz-Praga, S	1
Gong, K; Li, X; Liu, W; Luo, K; Wang, K	1
Baake, G; Boeck, S; Clemens, MR; Gauler, TC; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Höhler, T; Jung, A; Kettner, E; Klein, S; Ko, YD; Kojouharoff, G; Märten, A; Neugebauer, S; Rubanov, O; Vehling-Kaiser, U; von Weikersthal, LF; Waldschmidt, D; Winkelmann, C	1
Behrman, SW; Chitkara, D; Danquah, M; Kumar, N; Kumar, V; Mahato, RI; Singh, S	1
Ramfidis, VS; Saif, MW; Strimpakos, AS; Syrigos, KN	1
Braunfeld, J; Brekken, RA; Burrows, FJ; Carbon, JG; Kirane, A; Ostapoff, K; Schwarz, RE; Toombs, JE; Zaknoen, S	1
O'Reilly, EM	1
Choi, M; Kim, R; Razzaque, S	1
Ding, N; Tang, L; Wang, S; Wu, Y; Xiao, G; Xiao, Z	1
Arcaroli, J; Cusatis, G; Garrett-Mayer, E; Hidalgo, M; Messersmith, WA; Rubio-Viqueira, B; Song, D; Weekes, CD; Wilson, LA; Winn, RA	1
Barbacid, M; Guerra, C; Hernández-Porras, I; Navas, C; Schuhmacher, AJ; Sibilia, M	1
Drebin, JA; Pippin, JA; Singla, S	1
Clynes, M; Corkery, B; Crown, J; Kennedy, S; Larkin, A; O'Donovan, N; O'Driscoll, L; Walsh, N	1
Barner, M; Boeck, S; Clemens, MR; Egg, R; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Goritschan, C; Greten, TF; Heinemann, V; Jung, A; Kirchner, T; Klein, S; Kojouharoff, G; Laubender, RP; Mansmann, U; Märten, A; Neumann, J; Vehling-Kaiser, U; Winkelmann, C	1
Jaster, R; Kossow, C; Lange, F; Rateitschak, K; Wolkenhauer, O	1
Krug, S; Michl, P	1
Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H	1
Cai, H; Canto, MI; Chang, KJ; Donehower, RC; Herman, JM; Hoffe, SE; Klapman, J; Laheru, DA; Pawlik, TM; Reid, T; Rosemurgy, A; Savage, DT; Shah, RJ; Taylor, GE; Tran, PT; Wang, H; Wild, AT; Wolfgang, CL; Ziegler, MA	1
Arcaroli, J; Dasari, A; Erlichman, C; Foster, NR; Hidalgo, M; McManus, M; Messersmith, WA; Nallapareddy, S; Picus, J; Powell, R; Quackenbush, K; Tan, AC; Wright, J	1
Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM	1
Asaoka, Y; Ijichi, H; Ikenoue, T; Isayama, H; Koike, K; Miyabayashi, K; Mohri, D; Morishita, Y; Moses, HL; Nakai, Y; Omata, M; Tada, M; Tateishi, K; Yamamoto, K	1
Aldana, GQ; DE LA Cámara Gómez, J; Fernández, MJ; Fernández, MS; Folgar, SC; López, MR; López, R; Méndez, CM; Reinoso, CR; Vázquez, MR	1
Hedley, DW; Ng, SS; Nicklee, T; Tsao, MS	1
Aebi, S; Borner, MM; Büchler, MW; Friess, H; Kralidis, E	1
Depisch, D; Haider, K; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H; Verena Kornek, G	1
Gallagher, N; Smith, D	1
Gerst, B; Höpfner, M; Scherübl, H; Sutter, AP; Zeitz, M	1
Bloomston, PM; Cojita, D; Durkin, AJ; Giarelli, N; Rosemurgy, AS; Yeatman, TJ; Zervos, EE	1
Büchler, MW; Friess, H; Giese, N; Kleeff, J; Korc, M; Li, J	1
Arends, JJ; de Jong, RS; Leys, MB; Nortier, JW; Sleeboom, HP; Smit, JM; Ten Bokkel Huinink, D; Tesselaar, ME	1
Caenepeel, P; Demols, A; Houbiers, G; Leleux, A; Peeters, M; Polus, M; Van Cutsem, E; Van Laethem, JL; Van Maele, P; Vermaut, RR; Verslype, C	1
Lutz, MP	1
Ames, MM; Gilbert, JA; Lloyd, RV	1
Barthélemy, P; Bennouna, J; Bourgeois, H; Dorval, E; Douillard, JY; François, E; Hebbar, M; Martin, C; Mayeur, D; Perrier, H	1
Egami, H; Hirota, M; Ogawa, M; Takai, E; Tamori, Y; Tan, X	1
Gallmeier, E; Kern, SE	1
Amadori, D; Brigliadori, G; Fabbri, F; Granato, AM; Rosetti, M; Tesei, A; Ulivi, P; Vannini, I; Zoli, W	1
Burris, HA	1
Ko, AH; Tempero, MA	1
Pao, W; Riely, GJ	1
Abe, M; Egami, H; Hirota, M; Nozawa, F; Ogawa, M; Tan, X	1
Akerman, P; Barnett, JM; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Kennedy, T; Maia-Acuna, C; Martel, D; Miner, T; Remis, M; Safran, H	1
Moore, MJ	1
Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH	1
Bendell, JC; Blobe, GC; Clary, BM; Czito, BG; Fernando, NH; Honeycutt, W; Hurwitz, HI; Ludwig, KA; Mantyh, CR; Morse, MA; Pappas, TN; Tyler, DS; Willett, CG; Yu, D	1
Aprile, G; Balzano, G; Bonetto, E; Brandes, AA; Cordio, S; Dell'Oro, S; Di Carlo, V; Fugazza, C; Luppi, G; Milandri, C; Nicoletti, R; Pasetto, L; Passoni, P; Piemonti, L; Reni, M; Zerbi, A	1
Giaccone, G	1
de Jager, J; Stebbing, J	1
Abbruzzese, JL; Baker, CH; Cognetti, F; McConkey, DJ; Pino, MS; Shrader, M; Xiong, HQ	1
Armstrong, C; Durkin, AJ; Osborne, DA; Rosemurgy, AS; Yeatman, TJ; Zervos, EE	1
Maekawa, M; Okusaka, T; Yamada, T	1
Buck, E; Cagnoni, P; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK	1
Augé, JM; Ayuso, C; Cajal, R; Conill, C; Fernández-Cruz, L; Gallego, R; Gascón, P; Ginès, A; Marmol, M; Martin-Richard, M; Maurel, J; Miquel, R; Nadal, C; Navarro, S; Petriz, L; Sánchez, M	1
Nau, JY	1
Giaccone, G; Hoekman, K; Kater, M; Manoliu, RA; Meijerink, MR; van Cruijsen, H; van Schaik, C; van Waesberghe, JH	1
Abbruzzese, J; Ali, IF; Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH	1
Brown, E; Buck, E; Eyzaguirre, A; Gibson, NW; Griffin, G; Haley, JD; Iwata, KK; McCormack, S; Petti, F	1
Bianco, C; Ciardiello, F; Cionini, L; Danesi, R; de Liguoro, M; Del Tacca, M; Eckhardt, G; Giovannetti, E; Mey, V; Nannizzi, S; Pasqualetti, F; Raben, D; Ricciardi, S; Tortora, G; Troiani, T	1
Dragovich, T; Hage, G; Hamilton, M; Huberman, M; Nadler, P; Patnaik, A; Rowinsky, EK; Von Hoff, DD; Wolf, J; Wood, D	1
Ramanarayanan, J; Scarpace, SL	1
Altiok, S; Hidalgo, M; Iacobuzio-Donahue, C; Jimeno, A; Maitra, A; Mezzadra, H; Nielsen, ME; Rubio-Viqueira, B; Zhang, X	1
Barr, S; Buck, E; Cagnoni, P; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK; Sennello, R; Thompson, S; Young, D	1
Amador, ML; Grunwald, V; Hidalgo, M; Iacobuzio-Donahue, C; Jimeno, A; Maitra, A; Rubio-Viqueira, B	1
Barge, A; Bruns, CJ; Conrad, C; Geissler, EK; Guba, M; Ischenko, I; Jauch, KW; Köhl, G; Ryan, AJ; Wedge, SR; Wiegand, U; Yezhelyev, M	1
Boeck, S; Heinemann, V; Moosmann, N; Stemmler, HJ	1
Kindler, HL	1
Boige, V; Ducreux, M; Malka, D	1
Au, HJ; Campos, D; Clark, G; Ding, K; Figer, A; Gallinger, S; Goldstein, D; Hamm, J; Hecht, JR; Lim, R; Moore, MJ; Murawa, P; Parulekar, W; Ptasynski, M; Voskoglou-Nomikos, T; Walde, D; Wolff, RA	1
Arnoletti, JP; Buchsbaum, DJ; Frolov, A; Frolova, N; Heslin, MJ; Howard, JH; Jhala, NC; Tzeng, CW; Vickers, SM	2
Arnoletti, JP; Buchsbaum, DJ; Cannon, EE; Frolov, A; Heslin, MJ; Howard, JH; Ku, BC; Schuller, K; Tzeng, CW; Vickers, SM	1
Moore, MJ; Welch, SA	1
Burtness, B	1
Cagnoni, PJ; Clark, G; Nagrani, T; Wacker, B; Weinberg, J; Witt, K	1
Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E	1
Hu, WG; Liu, T; Wang, CY; Xiong, JX	1
Christophylakis, C; Georgoulias, V; Ignatiadis, M; Kalbakis, K; Kotsakis, A; Polyzos, A; Potamianou, A; Stathopoulos, GP; Tselepatiotis, E; Vamvakas, L	1
Brand, RE; Carneiro, BA; Fine, E; Khandekar, JD; Knop, RH; Locker, GY; Uhlig, W	1
Kibble, A	1
Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C	1
Boeck, S; Heinemann, V; Wollenberg, A	1
Cusack, JC; Lee, SW; Sloss, C; Wang, F; Zhang, X	1
Capanu, M; Duffy, A; Kelsen, DP; Kortmansky, J; Minsky, B; O'Reilly, EM; Puleio, S; Saltz, L; Schwartz, GK	1
Ferretti, G; Labianca, R; Mandalà, M; Moro, C	1
Goldstein, M; Miksad, RA; Schnipper, L	1
Alexandru, A; Dediu, M; Gal, C; Median, D; Vremes, G	1
Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX	1
Miller, JD	1
De Luca, A; Normanno, N	1
Philip, PA	1
Azzariti, A; Gatti, G; Nicolin, A; Paradiso, A; Porcelli, L	1
Johnson, JR; Justice, R; Pazdur, R; Senderowicz, AM; Sridhara, R; Zimmerman, P	1
Epstein, RJ; Leung, TW	1
Matuszczak, J; Rajebi, MR; Saif, MW; Shahrokni, A	1
Kim, YT	1
Burris, H; Rocha-Lima, C	1
Chua, YJ; Zalcberg, JR	1
Van Laethem, JL	1
Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D	1
Krishnan, GS; Ramanarayanan, J	1
Coffa, J; Diosdado, B; Hidalgo, M; Hirsch, FR; Iacobuzio-Donahue, C; Jimeno, A; Kulesza, P; Maitra, A; Meijer, GA; Messersmith, WA; Rajeshkumar, NV; Rubio-Viqueira, B; Tan, AC; Varella-Garcia, M; Wheelhouse, J	1
Rocha-Lima, CM	1
Merikas, I; Saif, MW; Syrigos, K; Tsimboukis, S	1
Danese, MD; Lin, CY; Lubeck, D; Northridge, K; O'Connor, P; Reyes, C	1
Abbruzzese, JL; Casper, ES; Douglass, HO; Fuchs, C; Meropol, NJ; Pazdur, R; Vincent, M	1
Farrelly, ER; Ho, JJ; Kim, YS	1
Firby, PS; Hedley, DW; Moore, MJ; Rauchwerger, DR	1
Adrian, TE; Cluck, MW; Knezetic, JA; Larsson, J; Lovas, S; Murphy, LO; Murphy, RF; Otvös, F; Permert, J; Schally, AV	1
Norman, P	1
Carlson, RW; Doroshow, JH; Flam, MS; Lamborn, KR; Malec, M; Odujinrin, OO	1
Bissery, MC; Corbett, TH; Luk, GD; Mucci-LoRusso, P; Plowman, J; Polin, L; Valeriote, F	1

Reviews

52 review(s) available for quinazolines and Pancreatic Neoplasms

Article	Year
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review . Clinical nephrology, 2018, Volume: 90, Issue:2 Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kidney Failure, Chronic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Renal Dialysis; Taxoids	2018
Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PloS one, 2013, Volume: 8, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2013
First-line treatment for advanced pancreatic cancer. JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic	2013
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Survival; Taxoids	2013
Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review. Pancreas, 2013, Volume: 42, Issue:5 Topics: Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2013
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials. Respiratory medicine, 2013, Volume: 107, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors	2013
Target therapies in pancreatic carcinoma. Current medicinal chemistry, 2014, Volume: 21, Issue:8 Topics: Albumins; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Matrix Metalloproteinases; Molecular Targeted Therapy; Paclitaxel; Pancreas; Pancreatic Neoplasms; Quinazolines; Receptor, IGF Type 1; Signal Transduction	2014
[Current status and future directions of chemotherapy for pancreatic cancer]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2013, Volume: 110, Issue:12 Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Tegafur	2013
[Targeted therapies, prognostic and predictive factors in endocrine oncology]. Annales d'endocrinologie, 2013, Volume: 74 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome	2013
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chinese journal of cancer, 2014, Volume: 33, Issue:6 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor	2014
Erlotinib. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2014, Volume: 201 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2014
Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature review. Tumori, 2015, Jul-24, Volume: 101, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autopsy; Critical Care; Diagnosis, Differential; Erlotinib Hydrochloride; Fatal Outcome; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lymphatic Metastasis; Male; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pulmonary Alveoli; Quinazolines; Tomography, X-Ray Computed	2015
Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? Current opinion in oncology, 2008, Volume: 20, Issue:4 Topics: Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design	2008
Novel advances in pancreatic cancer treatment. Expert review of anticancer therapy, 2008, Volume: 8, Issue:6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Delivery Systems; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome	2008
Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer control : journal of the Moffitt Cancer Center, 2008, Volume: 15, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines	2008
[Treatment of advanced pancreatic carcinoma]. Onkologie, 2008, Volume: 31 Suppl 5 Topics: Antineoplastic Agents; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Platinum; Quinazolines; Terminal Care	2008
[Medical-oncological aspects in the treatment of pancreatic cancer]. Der Radiologe, 2009, Volume: 49, Issue:2 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Survival Rate	2009
Skin toxicities associated with epidermal growth factor receptor inhibitors. Targeted oncology, 2009, Volume: 4, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Head and Neck Neoplasms; Humans; Mice; Pancreatic Neoplasms; Patient Education as Topic; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Vitamin K 3	2009
Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap? JOP : Journal of the pancreas, 2009, May-18, Volume: 10, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2009
Erlotinib. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 184 Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2010
Palliative chemotherapy for pancreatic malignancies. The Surgical clinics of North America, 2010, Volume: 90, Issue:2 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus	2010
Molecular therapy of pancreatic cancer. Minerva endocrinologica, 2010, Volume: 35, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A	2010
[New data on pancreatic cancer]. Onkologie, 2010, Volume: 33 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic	2010
Challenges of drug resistance in the management of pancreatic cancer. Expert review of anticancer therapy, 2010, Volume: 10, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Tumor Microenvironment	2010
Targeting EGFR in bilio-pancreatic and liver carcinoma. Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib	2011
A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer. Drug safety, 2011, Mar-01, Volume: 34, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment	2011
Metastatic pancreatic cancer: old drugs, new paradigms. Current opinion in oncology, 2011, Volume: 23, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines	2011
[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results]. Bulletin du cancer, 2011, Volume: 98, Issue:12 Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic	2011
Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World journal of gastroenterology, 2012, Feb-28, Volume: 18, Issue:8 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib	2012
Novel agents in early phase clinical studies on refractory pancreatic cancer. JOP : Journal of the pancreas, 2012, Mar-10, Volume: 13, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Ipilimumab; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents	2012
Targeting EGFR in pancreatic cancer treatment. Current drug targets, 2012, Volume: 13, Issue:6 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2012
Adjuvant therapy for pancreas adenocarcinoma. Journal of surgical oncology, 2013, Volume: 107, Issue:1 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Quinazolines; Treatment Outcome	2013
Systemic therapy of advanced pancreatic cancer: has the landscape changed? Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:7 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2012
New developments in pancreatic cancer treatment. Minerva gastroenterologica e dietologica, 2012, Volume: 58, Issue:4 Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome	2012
Recent updates on the role of chemotherapy in pancreatic cancer. Seminars in oncology, 2005, Volume: 32, Issue:4 Suppl 6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines	2005
Systemic therapy for pancreatic cancer. Seminars in radiation oncology, 2005, Volume: 15, Issue:4 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pemetrexed; Quinazolines	2005
Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Future oncology (London, England), 2005, Volume: 1, Issue:4 Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2005
[Molecular-based treatment concepts in advanced pancreatic cancer]. Deutsche medizinische Wochenschrift (1946), 2007, Apr-13, Volume: 132, Issue:15 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Metalloproteases; Molecular Biology; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A	2007
Pancreatic cancer: an update. Current oncology reports, 2007, Volume: 9, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines	2007
Treatment of advanced pancreatic cancer. Seminars in oncology, 2007, Volume: 34, Issue:2 Suppl 1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Survival Rate	2007
Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer. Future oncology (London, England), 2007, Volume: 3, Issue:3 Topics: Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2007
Her signaling in pancreatic cancer. Expert opinion on biological therapy, 2007, Volume: 7, Issue:6 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Epidermal Growth Factor; Erlotinib Hydrochloride; Gemcitabine; Humans; Lapatinib; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome	2007
[Treatments of pancreatic cancer from the standpoint of medical oncology]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Survival Rate; Tegafur	2007
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2007, Volume: 12 Suppl 1 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pancreatic Neoplasms; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome	2007
[Chemotherapy for pancreatic cancer]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2008, Volume: 51, Issue:2 Topics: Antimetabolites; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2008
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. The oncologist, 2008, Volume: 13, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Benzenesulfonates; Bevacizumab; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib	2008
Pancreatic cancer--is the wall crumbling? Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorouracil; Forecasting; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis	2008
[Pancreatic cancer: ten years of systemic therapy]. Bulletin du cancer, 2008, Volume: 95, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines	2008
Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:3 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Liver; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2008
Review: hepatotoxicity and EGFR inhibition. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:3 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2008
New directions in the management of advanced pancreatic cancer: a review. Anti-cancer drugs, 2008, Volume: 19, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Quinazolines	2008
Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP : Journal of the pancreas, 2008, May-08, Volume: 9, Issue:3 Topics: Algorithms; Antineoplastic Agents; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Genes, erbB-1; Humans; Incidence; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome	2008

Trials

76 trial(s) available for quinazolines and Pancreatic Neoplasms

Article	Year
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. Journal of gastroenterology, 2013, Volume: 48, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cross-Over Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome	2013
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8 Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate	2013
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. International journal of radiation oncology, biology, physics, 2013, Jul-15, Volume: 86, Issue:4 Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated	2013
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World journal of gastroenterology, 2013, Jul-28, Volume: 19, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Patient Selection; Proportional Hazards Models; Prospective Studies; Quinazolines; Time Factors; Treatment Outcome	2013
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer medicine, 2014, Volume: 3, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Quinazolines; Sorafenib	2014
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome	2014
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study. American journal of clinical oncology, 2011, Volume: 34, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure	2011
Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Prospective Studies; Protein Kinase Inhibitors; Quinazolines	2014
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:11 Topics: Adolescent; Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Drug Administration Schedule; Equilibrative Nucleoside Transporter 1; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Prospective Studies; Quinazolines; Rabbits; Survival Analysis; Treatment Outcome; Young Adult	2014
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:11 Topics: Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2014
Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphopenia; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Quinazolines; Radiography; Severity of Illness Index; Survival Analysis; Tumor Burden	2014
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate	2014
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer, 2014, Oct-01, Volume: 120, Issue:19 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Insulin-Like Growth Factor I; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome	2014
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC cancer, 2014, Aug-28, Volume: 14 Topics: Adult; Biomarkers, Tumor; eIF-2 Kinase; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Analysis; Tumor Suppressor Protein p53; Young Adult	2014
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. British journal of cancer, 2014, Nov-25, Volume: 111, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines	2014
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014, Volume: 113, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome	2014
Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer. British journal of cancer, 2015, Mar-17, Volume: 112, Issue:6 Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Treatment Outcome	2015
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:7 Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Metformin; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Netherlands; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome	2015
Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome	2015
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. British journal of cancer, 2015, Nov-17, Volume: 113, Issue:10 Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome	2015
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Investigational new drugs, 2016, Volume: 34, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Quinazolines; Treatment Outcome	2016
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet. Oncology, 2017, Volume: 18, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Prognosis; Quinazolines; Survival Rate	2017
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer investigation, 2008, Volume: 26, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Diseases; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Genes, ras; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Receptor, ErbB-2; Survival Analysis	2008
Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology, 2009, Volume: 76, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Taxoids	2009
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, May-01, Volume: 27, Issue:13 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines	2009
Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to the American journal of clinical oncology, 2009, Volume: 32, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; DNA Mutational Analysis; Female; Gefitinib; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiotherapy, Conformal; ras Proteins; Survival Rate	2009
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. Anti-cancer drugs, 2010, Volume: 21, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas, Exocrine; Pancreatic Neoplasms; Prospective Studies; Quinazolines	2010
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome	2009
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Investigational new drugs, 2011, Volume: 29, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunohistochemistry; Isoflavones; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines	2011
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2010
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC cancer, 2010, Jul-14, Volume: 10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Phosphorylation; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases	2010
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer, 2010, Dec-15, Volume: 116, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Canada; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Dosage; Humans; Mutation; Pancreatic Neoplasms; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome	2010
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival; Treatment Outcome	2011
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Annals of surgical oncology, 2011, Volume: 18, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome	2011
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Canada; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Treatment Outcome; Tumor Burden	2012
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer science, 2011, Volume: 102, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Adenosquamous; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines	2011
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational new drugs, 2012, Volume: 30, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Gene Amplification; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome; Xeroderma Pigmentosum Group D Protein	2012
Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:4 Topics: Adenocarcinoma, Mucinous; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Mucin 5AC; Pancreatic Neoplasms; Quinazolines	2011
Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer. International journal of radiation oncology, biology, physics, 2012, Feb-01, Volume: 82, Issue:2 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infections; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Time Factors; Tumor Burden; Vomiting	2012
Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Molecular cancer therapeutics, 2011, Volume: 10, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Genes, ras; Humans; Middle Aged; Mutation; Pancreatic Neoplasms; Quinazolines; Treatment Outcome	2011
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. Oncology, 2011, Volume: 81, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Piperidines; Quinazolines; Survival Rate; Treatment Outcome	2011
Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:10 Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Placebos; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk	2012
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome	2012
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PloS one, 2012, Volume: 7, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Pulmonary Embolism; Quinazolines; Treatment Outcome	2012
A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Investigational new drugs, 2012, Volume: 30, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines	2012
A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma. American journal of clinical oncology, 2013, Volume: 36, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome	2013
Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome	2012
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut, 2013, Volume: 62, Issue:5 Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome	2013
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. British journal of cancer, 2013, Feb-05, Volume: 108, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins	2013
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. Chemotherapy, 2012, Volume: 58, Issue:5 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Stomatitis; Vomiting	2012
Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Mar-01, Volume: 31, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Treatment Failure	2013
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer medicine, 2012, Volume: 1, Issue:2 Topics: 3' Untranslated Regions; Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzodioxoles; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Insulin-Like Growth Factor Binding Protein 2; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Quinazolines; Receptors, Cell Surface; src-Family Kinases	2012
Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study). Anticancer research, 2013, Volume: 33, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines	2013
Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Thiophenes; Treatment Outcome; Vomiting	2003
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. British journal of cancer, 2003, Apr-22, Volume: 88, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Time Factors; Treatment Outcome	2003
A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer. European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:10 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis	2003
A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma. British journal of cancer, 2005, Feb-14, Volume: 92, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Survival Rate; Thiophenes	2005
Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study. Oncology, 2004, Volume: 67, Issue:5-6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Belgium; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome	2004
A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma. Oncology, 2005, Volume: 68, Issue:4-6 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Quinazolines; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome	2005
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. American journal of clinical oncology, 2005, Volume: 28, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome	2005
Brief communication: a new combination in the treatment of advanced pancreatic cancer. Seminars in oncology, 2005, Volume: 32, Issue:6 Suppl 8 Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Survival Rate	2005
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-01, Volume: 24, Issue:4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Rectal Neoplasms	2006
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Salvage Therapy; Survival Analysis; Thiophenes	2006
Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics, 2006, Dec-01, Volume: 66, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gefitinib; Gemcitabine; Humans; Interleukin-8; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Radiotherapy Dosage; Vascular Endothelial Growth Factor A	2006
The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. European radiology, 2007, Volume: 17, Issue:7 Topics: Administration, Oral; Adult; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Contrast Media; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gefitinib; Humans; Image Processing, Computer-Assisted; Injections, Intravenous; Liver Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Pancreatic Neoplasms; Pelvic Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Tomography, Spiral Computed	2007
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-20, Volume: 25, Issue:15 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; International Agencies; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Prognosis; Quinazolines; Survival Rate; Treatment Outcome	2007
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jul-01, Volume: 13, Issue:13 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2007
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology, 2006, Volume: 71, Issue:3-4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Taxoids	2006
Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma. Cancer investigation, 2007, Volume: 25, Issue:5 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines	2007
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Treatment Outcome	2008
Improving treatment of pancreatic cancer. The Lancet. Oncology, 2008, Volume: 9, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2008
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:14 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis	2007
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. American journal of clinical oncology, 2008, Volume: 31, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis	2008
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Investigational new drugs, 1996, Volume: 13, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase	1996
Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group. Investigational new drugs, 1990, Volume: 8, Issue:4 Topics: Adenocarcinoma; Antineoplastic Agents; Drug Evaluation; Drugs, Investigational; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Trimetrexate	1990

Other Studies

196 other study(ies) available for quinazolines and Pancreatic Neoplasms

Article	Year
Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers. Cancer science, 2021, Volume: 112, Issue:11 Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Discovery; Female; Gene Silencing; Humans; Kinesins; Libraries, Special; Metaphase; Mice; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays	2021
RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging. Molecular imaging and biology, 2022, Volume: 24, Issue:3 Topics: Albumins; Amiloride; Animals; Antineoplastic Agents; Cell Line, Tumor; Dextrans; Humans; Lung Neoplasms; Mice; Mutation; Optical Imaging; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Quinazolines	2022
DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. Molecular cancer research : MCR, 2022, 07-06, Volume: 20, Issue:7 Topics: DNA-Activated Protein Kinase; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyridazines; Quinazolines; RNA Polymerase III	2022
Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma. Journal of medicinal chemistry, 2022, 10-13, Volume: 65, Issue:19 Topics: Animals; Carbon Isotopes; Carcinoma; Dogs; Humans; Mice; Nuclear Family; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; SOS1 Protein	2022
Pancreatic Stromal Cell-derived Oncostatin M Confers Drug Resistance to a Multi-tyrosine Kinase Inhibitor in Pancreatic Cancer Cells. Anticancer research, 2023, Volume: 43, Issue:6 Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Oncostatin M; Pancreas; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Stromal Cells; Tyrosine Kinase Inhibitors	2023
Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 10-20, Volume: 41, Issue:30 Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines	2023
Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells. Cellular oncology (Dordrecht), 2020, Volume: 43, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Radiation Tolerance; Snail Family Transcription Factors; Survivin; Vascular Endothelial Growth Factor A; X-Linked Inhibitor of Apoptosis Protein; Zinc Finger E-box-Binding Homeobox 1	2020
Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]. Cellular signalling, 2020, Volume: 68 Topics: Cell Line, Tumor; Cell Survival; Humans; MAP Kinase Signaling System; Models, Biological; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Quinolines; Receptor, ErbB-3; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Valproic Acid	2020
Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells. International journal of oncology, 2020, Volume: 56, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Humans; Mice; Mice, Nude; Microtubule-Associated Proteins; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays	2020
Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations. Briefings in bioinformatics, 2021, 05-20, Volume: 22, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Synergism; Female; Humans; Irinotecan; Male; Mutation; Pancreatic Neoplasms; Piperidines; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Rate; Tumor Suppressor Protein p53	2021
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. The oncologist, 2021, Volume: 26, Issue:7 Topics: Adenocarcinoma; Female; Humans; Mutation; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Quinazolines; Vascular Endothelial Growth Factor A	2021
Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells. International journal of molecular sciences, 2019, Jul-02, Volume: 20, Issue:13 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents	2019
Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2. Bioorganic & medicinal chemistry letters, 2019, 09-01, Volume: 29, Issue:17 Topics: Binding Sites; Cell Line, Tumor; Drug Design; Enzyme Inhibitors; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Histones; Humans; Inhibitory Concentration 50; Lysine; Molecular Docking Simulation; Pancreatic Neoplasms; Point Mutation; Quinazolines; Structure-Activity Relationship	2019
Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Humans; Lapatinib; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Signal Transduction	2013
[Pancreatic carcinoma]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 8 Topics: Erlotinib Hydrochloride; Everolimus; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus	2012
[Report from a small registry-permetrexed, tarceva and yondelis]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2013, Volume: 26, Issue:1 Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Mesothelioma; Pancreatic Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Registries; Sarcoma	2013
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Investigational new drugs, 2013, Volume: 31, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines	2013
Activated EGFR stimulates MUC1 expression in human uterine and pancreatic cancer cell lines. Journal of cellular biochemistry, 2013, Volume: 114, Issue:10 Topics: Blotting, Western; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression; Humans; Mucin-1; Pancreatic Neoplasms; Quinazolines; Rosiglitazone; Thiazolidinediones; Tyrphostins; Uterine Neoplasms	2013
Utilizing endoscopic ultrasound-guided fine needle aspiration in identifying molecular targets for pancreatic cancer. JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4 Topics: Endoscopic Ultrasound-Guided Fine Needle Aspiration; Erlotinib Hydrochloride; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Reproducibility of Results	2013
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Peptide Fragments; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Telomerase; Treatment Outcome; Vaccines	2013
New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma. JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Docetaxel; Erlotinib Hydrochloride; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome	2013
[A case of pancreatic body cancer with multiple liver metastases experiencing long-term response by gemcitabine plus erlotinib therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:6 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Time Factors	2013
Cyclopamine increases the radiosensitivity of human pancreatic cancer cells by regulating the DNA repair signal pathway through an epidermal growth factor receptor‑dependent pathway. Molecular medicine reports, 2013, Volume: 8, Issue:4 Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; ErbB Receptors; Gefitinib; Histones; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Signal Transduction; Veratrum Alkaloids	2013
In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells. Hepato-gastroenterology, 2013, Volume: 60, Issue:126 Topics: Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lapatinib; Pancreatic Neoplasms; Quinazolines; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins	2013
Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Molecular cancer, 2013, Sep-11, Volume: 12, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Tyrphostins; Xenograft Model Antitumor Assays	2013
Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy. Pancreas, 2013, Volume: 42, Issue:7 Topics: Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Platelet Count; Quinazolines; Splenectomy; Thrombocytosis	2013
Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma. International journal of radiation oncology, biology, physics, 2013, Nov-01, Volume: 87, Issue:3 Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smad4 Protein; Treatment Outcome	2013
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC cancer, 2013, Oct-02, Volume: 13 Topics: Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Follow-Up Studies; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Naphthalenes; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Pancreatic Neoplasms; Prognosis; Pyrimidinones; Quinazolines; Sirtuin 1	2013
microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions. Oncogene, 2014, Sep-18, Volume: 33, Issue:38 Topics: Acetyltransferases; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Epidermal Growth Factor; Erlotinib Hydrochloride; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 4; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Quinazolines; RNA Interference; Signal Transduction; Transcription Factors; Transforming Growth Factor beta	2014
Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10. Annals of surgical oncology, 2014, Volume: 21, Issue:2 Topics: Animals; Apoptosis; Cell Proliferation; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Oncolytic Virotherapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Simplexvirus; Survival Rate; Tumor Cells, Cultured; Virus Internalization; Virus Replication; Xenograft Model Antitumor Assays	2014
Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715. Molecular cancer therapeutics, 2014, Volume: 13, Issue:2 Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Pancreatic Neoplasms; Prognosis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Survival Analysis; Time Factors; Transcriptome	2014
Transcriptional regulation of Δ6-desaturase by peroxisome proliferative-activated receptor δ agonist in human pancreatic cancer cells: role of MEK/ERK1/2 pathway. TheScientificWorldJournal, 2013, Volume: 2013 Topics: Cell Line, Tumor; ErbB Receptors; Fatty Acid Desaturases; Flavonoids; Gene Expression Regulation, Enzymologic; Humans; MAP Kinase Signaling System; Pancreatic Neoplasms; PPAR delta; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Neoplasm; Thiazoles; Tyrphostins	2013
[Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines	2013
Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer. Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:12 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Genes, Lethal; Humans; MAP Kinase Signaling System; Mice; Pancreatic Neoplasms; Quinazolines; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Small Interfering	2013
Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice. JOP : Journal of the pancreas, 2014, Jan-10, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Eruptions; Drug Evaluation; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome	2014
PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug. Pancreas, 2014, Volume: 43, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Plant Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Ribosome Inactivating Proteins, Type 1; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays	2014
Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer medicine, 2014, Volume: 3, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lymphocytes; Male; Neutrophils; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quinazolines; Survival Analysis; Tegafur; Treatment Outcome	2014
Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer biology & therapy, 2014, Volume: 15, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Caffeine; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Purinergic P1 Receptor Agonists; Quinazolines; Signal Transduction; Triazoles	2014
CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. Oncotarget, 2014, Apr-15, Volume: 5, Issue:7 Topics: Aged; Animals; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Survival Rate; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Ubiquitination	2014
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Investigational new drugs, 2014, Volume: 32, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53	2014
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Aug-01, Volume: 20, Issue:15 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2014
Serum cytokine profile in patients with pancreatic cancer. Pancreas, 2014, Volume: 43, Issue:7 Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Comorbidity; Cytokines; Deoxycytidine; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking; Tumor Microenvironment	2014
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea. Pancreas, 2014, Volume: 43, Issue:7 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome	2014
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward. JOP : Journal of the pancreas, 2014, Jul-28, Volume: 15, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Taxoids; Treatment Outcome	2014
Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. The oncologist, 2014, Volume: 19, Issue:9 Topics: Biomarkers, Tumor; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Neoplasm Staging; Pancreatic Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2014
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression. European journal of clinical investigation, 2014, Volume: 44, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome	2014
Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies. Molecular therapy : the journal of the American Society of Gene Therapy, 2014, Volume: 22, Issue:12 Topics: Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Genetic Vectors; Humans; Lapatinib; Lentivirus; Molecular Targeted Therapy; Mutagenesis, Insertional; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Quinazolines	2014
Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity. Science China. Life sciences, 2014, Volume: 57, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, ras; Green Fluorescent Proteins; Humans; Mutation; Pancreas; Pancreatic Neoplasms; Plasmids; Quinazolines; ras Proteins; Recombinant Proteins	2014
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Jan-15, Volume: 21, Issue:2 Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Humans; MAP Kinase Kinase Kinases; Mice, Transgenic; Morpholines; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines	2015
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. Scandinavian journal of gastroenterology, 2014, Volume: 49, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome	2014
Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer. Anticancer research, 2014, Volume: 34, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Combined Modality Therapy; Deoxycytidine; Endoscopy, Digestive System; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gastritis; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries; Radiography; Thymidine Phosphorylase; Withholding Treatment	2014
Inhibition of progression of PanIN through antagonizing EGFR. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:5 Topics: Animals; Antineoplastic Agents; Carcinoma in Situ; Disease Progression; Drug Screening Assays, Antitumor; ErbB Receptors; Male; Mice, Transgenic; Pancreas; Pancreatic Neoplasms; Quinazolines; Tyrphostins	2015
mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer. International journal of molecular sciences, 2015, Feb-03, Volume: 16, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Forkhead Transcription Factors; Humans; Morpholines; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays	2015
Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Oncotarget, 2015, Mar-10, Volume: 6, Issue:7 Topics: Afatinib; Animals; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Morpholines; Mucin-4; Pancreatic Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2015
Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib. Bioorganic & medicinal chemistry letters, 2015, Mar-15, Volume: 25, Issue:6 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glycosylation; Humans; Metabolic Engineering; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; STAT Transcription Factors	2015
A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy. Neoplasia (New York, N.Y.), 2015, Volume: 17, Issue:2 Topics: Animals; Anti-Arrhythmia Agents; Blotting, Western; Carcinoma, Pancreatic Ductal; Cation Transport Proteins; Cell Line; Cell Line, Tumor; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Guanidines; Humans; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sulfones	2015
Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report. World journal of gastroenterology, 2015, Mar-21, Volume: 21, Issue:11 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Crown Ethers; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2015
[Erlotinib, sunitinib, and everolimus]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 3 Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Everolimus; Humans; Indoles; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sirolimus; Sunitinib	2015
Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors. BMC cancer, 2015, Apr-04, Volume: 15 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lapatinib; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured	2015
Functionalized gold nanoparticles improve afatinib delivery into cancer cells. Expert opinion on drug delivery, 2016, Volume: 13, Issue:1 Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Gold; Humans; Inhibitory Concentration 50; Nanoparticles; Pancreatic Neoplasms; Polyethylene Glycols; Protein-Tyrosine Kinases; Quinazolines	2016
Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:2 Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; DNA; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Lysophospholipids; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transcriptional Activation	2016
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Oncotarget, 2015, Oct-20, Volume: 6, Issue:32 Topics: Animals; Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Carcinoma, Pancreatic Ductal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; ErbB Receptors; Female; Gefitinib; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Signal Transduction	2015
Pancreatic Tumor Progression Associated With CD133 Overexpression: Involvement of Increased TERT Expression and Epidermal Growth Factor Receptor-Dependent Akt Activation. Pancreas, 2016, Volume: 45, Issue:3 Topics: AC133 Antigen; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Telomerase; Transplantation, Heterologous	2016
Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. Targeted oncology, 2016, Volume: 11, Issue:3 Topics: Adenocarcinoma; Afatinib; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Pancreatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Signal Transduction	2016
Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. International journal of oncology, 2016, Volume: 48, Issue:1 Topics: Apoptosis; Autophagy; Azithromycin; Cell Line, Tumor; Clarithromycin; Drug Synergism; ErbB Receptors; Erythromycin; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Macrolides; Pancreatic Neoplasms; Quinazolines	2016
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. International journal of oncology, 2016, Volume: 48, Issue:3 Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Crizotinib; Cyclic S-Oxides; Deoxycytidine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Ligands; MAP Kinase Signaling System; Mutation; Pancreatic Neoplasms; Phenotype; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor	2016
Identification of drugs that restore primary cilium expression in cancer cells. Oncotarget, 2016, Mar-01, Volume: 7, Issue:9 Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cilia; Drug Screening Assays, Antitumor; Gefitinib; Humans; Microscopy, Confocal; Neoplasms; Pancreatic Neoplasms; Quinazolines; Reproducibility of Results	2016
Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. Cancer letters, 2016, 08-28, Volume: 379, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Female; Gene Expression Profiling; Genes, Retinoblastoma; Genetic Predisposition to Disease; Humans; Lapatinib; Lymphangiogenesis; Male; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phenotype; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta	2016
Erlotinib: the first biologic in the management of pancreatic cancer. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:9 Topics: Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic	2008
Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor. Biochemical pharmacology, 2008, Jul-15, Volume: 76, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Humans; Kinesins; Mice; Mice, Nude; Pancreatic Neoplasms; Quinazolines; Thiones; Xenograft Model Antitumor Assays	2008
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Molecular cancer therapeutics, 2008, Volume: 7, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dinoprostone; DNA, Complementary; DNA, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescence; Humans; Indoles; Mice; NF-kappa B; Pancreatic Neoplasms; Protein Binding; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Transfection; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays	2008
Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:6 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Dizziness; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Hearing; Hearing Loss, Sensorineural; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Tinnitus; Treatment Failure	2008
Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Archives of dermatology, 2008, Volume: 144, Issue:7 Topics: Acitretin; Administration, Oral; Diagnosis, Differential; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Keratolytic Agents; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2008
Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-01, Volume: 14, Issue:15 Topics: Adenocarcinoma; Adult; Aged; Cell Line, Tumor; Cell Proliferation; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mesoderm; Microfilament Proteins; Middle Aged; Pancreatic Neoplasms; Phenotype; Quinazolines	2008
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays	2008
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunoblotting; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy; Xenograft Model Antitumor Assays	2008
Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World journal of gastroenterology, 2008, Sep-21, Volume: 14, Issue:35 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2008
Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. Journal of proteome research, 2008, Volume: 7, Issue:11 Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Humans; Immunohistochemistry; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Quinazolines; Substrate Specificity; Tumor Burden; Xenograft Model Antitumor Assays	2008
Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models. International journal of cancer, 2009, Jan-15, Volume: 124, Issue:2 Topics: Animals; Benzodioxoles; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hypoxia; Male; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor	2009
Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? The American journal of gastroenterology, 2009, Volume: 104, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Blotting, Western; Carcinoid Tumor; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Insulinoma; Male; Mice; Mice, Transgenic; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tyrphostins; Young Adult	2009
Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma. Bulletin of experimental biology and medicine, 2008, Volume: 145, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Gene Frequency; Genetic Predisposition to Disease; Humans; Pancreatic Neoplasms; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Quinazolines; Time Factors; Tumor Cells, Cultured; Tyrphostins	2008
Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP : Journal of the pancreas, 2009, May-18, Volume: 10, Issue:3 Topics: Bacteremia; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin; Staphylococcal Infections; Staphylococcus aureus	2009
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-15, Volume: 15, Issue:12 Topics: Animals; Antineoplastic Agents; Benzodioxoles; Biomarkers, Tumor; Female; Focal Adhesion Kinase 1; Gene Expression Profiling; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Paxillin; Proto-Oncogene Proteins pp60(c-src); Quinazolines; STAT3 Transcription Factor; Xenograft Model Antitumor Assays	2009
Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society. Oncology, 2009, Volume: 77, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Germany; Health Care Surveys; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Guidelines as Topic; Prognosis; Quinazolines; Radiotherapy Dosage; Surveys and Questionnaires; Treatment Outcome; Young Adult	2009
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP : Journal of the pancreas, 2009, Jul-06, Volume: 10, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome	2009
Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest. Anatomical record (Hoboken, N.J. : 2007), 2009, Volume: 292, Issue:8 Topics: Antineoplastic Agents; Aurora Kinase B; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; G2 Phase; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Quinazolines	2009
EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biological chemistry, 2009, Volume: 390, Issue:12 Topics: Amino Acid Sequence; Cell Line, Tumor; ErbB Receptors; Extracellular Matrix Proteins; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Pancreatic Neoplasms; Phosphorylation; Phylogeny; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Sequence Alignment	2009
ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines. Neuroendocrinology, 2010, Volume: 91, Issue:2 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Apoptosis; Aurora Kinases; Benzamides; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cell Division; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Interactions; Drug Therapy, Combination; Fluorouracil; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Octreotide; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Quinazolines; Somatostatin; Streptozocin; Survivin; Synaptophysin	2010
In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer. Cancer science, 2010, Volume: 101, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Combinations; Female; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Tegafur; Xenograft Model Antitumor Assays	2010
Erlotinib-induced trichomegaly in a male patient with pancreatic cancer. Cutaneous and ocular toxicology, 2010, Volume: 29, Issue:1 Topics: Aged; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Eyebrows; Eyelashes; Female; Humans; Hypertrichosis; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2010
Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer. Anticancer research, 2009, Volume: 29, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate; Time Factors	2009
A patient of situs ambiguus with pancreatic head cancer successfully treated with gemcitabine and erlotinib. Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Situs Inversus; Treatment Outcome	2011
Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Feb-01, Volume: 16, Issue:3 Topics: Animals; Cell Line, Tumor; ErbB Receptors; Female; Genes, ras; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mutation; Nelfinavir; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays	2010
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. Journal of cellular biochemistry, 2010, Volume: 110, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Indoles; Mice; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays	2010
Stromal depletion goes on trial in pancreatic cancer. Journal of the National Cancer Institute, 2010, Apr-07, Volume: 102, Issue:7 Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Hedgehog Proteins; Humans; Off-Label Use; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Survival Analysis; United States	2010
Any progress in pancreatic cancer? Well, but progress for Acta Oncologica. Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:4 Topics: Antineoplastic Agents; Clinical Trials as Topic; Congresses as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Journalism, Medical; Pancreatic Neoplasms; Quinazolines; Research Design; Treatment Failure	2010
Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines. Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:2 Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Thymidine Phosphorylase; Vascular Endothelial Growth Factor A	2010
ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer biology & therapy, 2010, Sep-15, Volume: 10, Issue:6 Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Morpholines; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays	2010
ERBB3: Multifunctional enabler or primary actor in pancreatic cancer? Cancer biology & therapy, 2010, Sep-15, Volume: 10, Issue:6 Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays	2010
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer research, 2010, Volume: 30, Issue:7 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids	2010
Hepatic failure and hepatorenal syndrome secondary to erlotinib: a possible etiology of complications in a patient with pancreatic cancer. JOP : Journal of the pancreas, 2010, Sep-06, Volume: 11, Issue:5 Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Fatal Outcome; Hepatorenal Syndrome; Humans; Liver Failure; Male; Pancreatic Neoplasms; Quinazolines	2010
Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-10, Volume: 28, Issue:29 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase II as Topic; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Immunosuppressive Agents; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mice; Mice, Transgenic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Repressor Proteins; RNA Interference; Signal Transduction; Sirolimus; Survival Analysis; Survivin; TOR Serine-Threonine Kinases; Treatment Outcome	2010
Small tumors, intermediate models, big hopes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-10, Volume: 28, Issue:29 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunosuppressive Agents; Intracellular Signaling Peptides and Proteins; Mice; Mice, Transgenic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome	2010
[Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2010, Volume: 32, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome	2010
Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: Antineoplastic Agents; Aurora Kinases; Benzamides; BRCA2 Protein; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Size; Cell Survival; Cytokinesis; Dose-Response Relationship, Drug; Female; Humans; Inhibitory Concentration 50; Mitosis; Molecular Targeted Therapy; Mutation; Pancreatic Neoplasms; Ploidies; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; RNA, Messenger; Transfection; Tumor Suppressor Protein p53	2012
Chemoprevention of pancreatic cancer: ready for the clinic? Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:11 Topics: Animals; Antineoplastic Agents; Chemoprevention; ErbB Receptors; Gefitinib; Humans; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2010
The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:11 Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Disease Models, Animal; Disease Progression; ErbB Receptors; Fluorescent Antibody Technique; Gefitinib; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pancreatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction	2010
Pancreatic cancer: will incremental advances begin to make a difference? Journal of the National Cancer Institute, 2010, Dec-15, Volume: 102, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure	2010
Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma. Pancreas, 2011, Volume: 40, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Pancreatic Neoplasms; Quinazolines	2011
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion	2011
Microcystic/reticular schwannoma of the pancreas: a potential diagnostic pitfall. Pathology international, 2011, Volume: 61, Issue:2 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Deoxycytidine; Diagnostic Errors; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neurilemmoma; Pancreatectomy; Pancreatic Neoplasms; Quinazolines	2011
Response to combined molecular targeting: defining the role of P-STAT3. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Feb-01, Volume: 17, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays	2011
Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Feb-01, Volume: 17, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays	2011
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. British journal of cancer, 2011, Mar-01, Volume: 104, Issue:5 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase B; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Nude; Organophosphates; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Quinazolines; Xenograft Model Antitumor Assays	2011
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-01, Volume: 17, Issue:9 Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Inbred ICR; Mice, SCID; Mice, Transgenic; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Xenograft Model Antitumor Assays	2011
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP : Journal of the pancreas, 2011, Mar-09, Volume: 12, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome	2011
Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome	2012
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature medicine, 2011, Volume: 17, Issue:4 Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; GATA6 Transcription Factor; Gemcitabine; Gene Expression Profiling; Humans; Male; Mice; Pancreatic Neoplasms; Pharmacogenetics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins	2011
Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report. BMC gastroenterology, 2011, Apr-07, Volume: 11 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glucocorticoids; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymyositis; Quinazolines; Radionuclide Imaging	2011
Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series. Anticancer research, 2011, Volume: 31, Issue:3 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines	2011
A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells. Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3 Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cisplatin; Culture Media; Deoxycytidine; Dioxoles; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gemcitabine; Humans; Mice; Mice, Transgenic; Pancreatic Neoplasms; Quinazolines; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Microenvironment	2011
Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2011, Volume: 99, Issue:2 Topics: Antimetabolites, Antineoplastic; Chi-Square Distribution; Combined Modality Therapy; Contrast Media; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiography, Interventional; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed	2011
Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma. British journal of cancer, 2011, Aug-09, Volume: 105, Issue:4 Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Communication; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Fibroblasts; Humans; Immunohistochemistry; Mice; Mice, SCID; Neuregulin-1; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transplantation, Heterologous	2011
Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. British journal of cancer, 2011, Nov-08, Volume: 105, Issue:10 Topics: Afatinib; Animals; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Colorimetry; Drug Screening Assays, Antitumor; Humans; Mice; Oncogene Proteins v-erbB; Pancreatic Neoplasms; Quinazolines; Xenograft Model Antitumor Assays	2011
Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5. Acta pharmacologica Sinica, 2011, Volume: 32, Issue:12 Topics: Allosteric Regulation; Cell Line, Tumor; Cell Movement; Humans; Kinesins; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Thiones	2011
Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma. International journal of radiation oncology, biology, physics, 2012, Jul-15, Volume: 83, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Area Under Curve; Combined Modality Therapy; Deoxycytidine; Duodenum; Erlotinib Hydrochloride; Female; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Quinazolines; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Risk Factors	2012
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Annals of surgical oncology, 2012, Volume: 19, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Length of Stay; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quinazolines; Survival Rate; Taxoids	2012
Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:11 Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Transfection; Tumor Cells, Cultured	2011
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts. Oncology reports, 2012, Volume: 27, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays	2012
Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. International journal of biological sciences, 2012, Volume: 8, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; NF-kappa B; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Quinazolines; Signal Transduction	2012
The management of EGFR inhibitor adverse events: a case series and treatment paradigm. International journal of dermatology, 2012, Volume: 51, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome	2012
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays	2012
Combination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9. Anticancer research, 2012, Volume: 32, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Pancreatic Neoplasms; Quinazolines	2012
The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas, 2013, Volume: 42, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Community Health Services; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Tennessee; Time Factors; Treatment Outcome	2013
Epidermal growth factor enhances MPC-83 pancreatic cancer cell migration through the upregulation of aquaporin 3. Molecular medicine reports, 2012, Volume: 6, Issue:3 Topics: Antineoplastic Agents; Aquaporin 3; Butadienes; Cell Line, Tumor; Cell Movement; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Nitriles; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Up-Regulation	2012
Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer. Molecular pharmaceutics, 2012, Aug-06, Volume: 9, Issue:8 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gefitinib; Humans; Male; Mice; Mice, Nude; Micelles; Pancreatic Neoplasms; Quinazolines; Veratrum Alkaloids	2012
Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress? JOP : Journal of the pancreas, 2012, Jul-10, Volume: 13, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Lapatinib; Leucovorin; Oligodeoxyribonucleotides; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Thionucleotides	2012
Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Sep-15, Volume: 18, Issue:18 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sulfonamides	2012
Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line. Anatomical record (Hoboken, N.J. : 2007), 2012, Volume: 295, Issue:12 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2012
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:8 Topics: Animals; Cell Line, Tumor; Chemokine CXCL12; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridines; Quinazolines; Receptors, CXCR; Receptors, CXCR4; RNA Interference; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transplantation, Heterologous; Tumor Microenvironment; Vascular Endothelial Growth Factor A	2012
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer cell, 2012, Sep-11, Volume: 22, Issue:3 Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cells, Cultured; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Mice; Mice, Transgenic; Pancreas; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; STAT3 Transcription Factor; Tumor Suppressor Protein p53	2012
Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer. Oncology reports, 2012, Volume: 28, Issue:6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Survivin	2012
EGFR and HER2 inhibition in pancreatic cancer. Investigational new drugs, 2013, Volume: 31, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2	2013
Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach. World journal of gastroenterology, 2012, Nov-21, Volume: 18, Issue:43 Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Replication; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Kinetics; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Molecular Targeted Therapy; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines	2012
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC cancer, 2013, Jan-31, Volume: 13 Topics: Afatinib; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Pancreatic Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1	2013
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer research, 2013, Apr-01, Volume: 73, Issue:7 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gemcitabine; Immunoenzyme Techniques; Immunoprecipitation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survival Rate; Tumor Cells, Cultured	2013
Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Molecular cancer therapeutics, 2002, Volume: 1, Issue:10 Topics: Adenocarcinoma; Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique, Indirect; Gemcitabine; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, SCID; Microscopy, Fluorescence; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Wortmannin	2002
A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). British journal of cancer, 2003, Nov-03, Volume: 89, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Fluorescent Antibody Technique; Gastrointestinal Neoplasms; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulinoma; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction	2003
Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. American journal of surgery, 2003, Volume: 186, Issue:5 Topics: Cell Line; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Immunohistochemistry; In Vitro Techniques; Pancreatic Neoplasms; Polymerase Chain Reaction; Quinazolines; Time Factors; Tumor Cells, Cultured	2003
Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. International journal of oncology, 2004, Volume: 25, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines	2004
[Chemotherapy of pancreatic carcinoma]. Praxis, 2005, Jun-01, Volume: 94, Issue:22 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids	2005
Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. The New England journal of medicine, 2005, Jul-14, Volume: 353, Issue:2 Topics: Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gastrointestinal Neoplasms; Gefitinib; Humans; Molecular Sequence Data; Mutation; Neuroendocrine Tumors; Pancreatic Neoplasms; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines	2005
Correlation of translocation of tight junction protein Zonula occludens-1 and activation of epidermal growth factor receptor in the regulation of invasion of pancreatic cancer cells. International journal of oncology, 2005, Volume: 27, Issue:3 Topics: Animals; BALB 3T3 Cells; Cell Line, Tumor; Cell Movement; Culture Media, Conditioned; Enzyme Inhibitors; ErbB Receptors; Humans; Membrane Proteins; Mice; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphoproteins; Phosphorylation; Protein Transport; Protein Tyrosine Phosphatases; Quinazolines; Tight Junctions; Tyrphostins; Zonula Occludens-1 Protein	2005
Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition. Cancer biology & therapy, 2005, Volume: 4, Issue:7 Topics: Adenocarcinoma; Apoptosis; Benzamides; BRCA2 Protein; Enzyme Inhibitors; Frameshift Mutation; Humans; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tumor Cells, Cultured; Tumor Stem Cell Assay	2005
Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. Cancer biology & therapy, 2005, Volume: 4, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Quinazolines	2005
Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important? Cancer biology & therapy, 2005, Volume: 4, Issue:10 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Pancreatic Neoplasms; Quinazolines	2005
Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway. Journal of clinical pathology, 2005, Volume: 58, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Blotting, Western; Butadienes; Culture Media, Conditioned; Down-Regulation; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Matrix Metalloproteinase 7; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Invasiveness; Nitriles; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Tight Junctions; Tumor Cells, Cultured; Tyrphostins	2005
Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Molecular cancer therapeutics, 2005, Volume: 4, Issue:12 Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Electrophoretic Mobility Shift Assay; ErbB Receptors; Erlotinib Hydrochloride; Humans; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Pyrazoles; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides	2005
Erlotinib or capecitabine with gemcitabine in pancreatic cancer? Future oncology (London, England), 2006, Volume: 2, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines	2006
Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer research, 2006, Apr-01, Volume: 66, Issue:7 Topics: Animals; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Signal Transduction; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays	2006
EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma. The Journal of surgical research, 2006, Volume: 135, Issue:1 Topics: Adenocarcinoma; Animals; Cell Division; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phenylalanine; Protease Inhibitors; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Thiophenes	2006
Serum tumor markers for pancreatic cancer: the dawn of new era? JOP : Journal of the pancreas, 2006, Jul-10, Volume: 7, Issue:4 Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; DNA Methylation; DNA, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteomics; Quinazolines; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2006
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Molecular cancer therapeutics, 2006, Volume: 5, Issue:8 Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Ribosomal Protein S6 Kinases; Signal Transduction; TOR Serine-Threonine Kinases	2006
[Pancreatic cancer: Roche versus the European Agency of Drugs]. Revue medicale suisse, 2006, Aug-23, Volume: 2, Issue:76 Topics: Drug Approval; Drug Industry; Erlotinib Hydrochloride; European Union; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2006
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer research, 2006, Nov-01, Volume: 66, Issue:21 Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Genistein; Humans; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction	2006
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Molecular cancer therapeutics, 2006, Volume: 5, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus	2006
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Dec-01, Volume: 12, Issue:23 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Deoxycytidine Kinase; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Gene Expression Profiling; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Piperidines; Polymerase Chain Reaction; Predictive Value of Tests; Quinazolines; Radiation, Ionizing; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Transplantation, Heterologous	2006
Acute drug induced hepatitis due to erlotinib. JOP : Journal of the pancreas, 2007, Jan-09, Volume: 8, Issue:1 Topics: Adenocarcinoma; Aged; Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2007
Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. Molecular cancer therapeutics, 2007, Volume: 6, Issue:2 Topics: Adenocarcinoma; Animals; Biopsy, Fine-Needle; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Xenograft Model Antitumor Assays	2007
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Molecular cancer therapeutics, 2007, Volume: 6, Issue:2 Topics: Biomarkers, Tumor; Cadherins; Cell Adhesion; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoenzyme Techniques; Mesoderm; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tissue Array Analysis; Vimentin	2007
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Molecular cancer therapeutics, 2007, Volume: 6, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biliary Tract Neoplasms; Biomarkers, Tumor; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays	2007
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anti-cancer drugs, 2007, Volume: 18, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Quinazolines; Regional Blood Flow; Signal Transduction; Skin; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2	2007
Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Annals of surgical oncology, 2007, Volume: 14, Issue:7 Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Introns; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Genetic; Postoperative Period; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome	2007
ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer biology & therapy, 2007, Volume: 6, Issue:4 Topics: Cell Line, Tumor; Cell Proliferation; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; RNA, Small Interfering	2007
Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. Acta pharmacologica Sinica, 2007, Volume: 28, Issue:8 Topics: Apoptosis; Cell Cycle; Cell Proliferation; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Veratrum Alkaloids	2007
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3. IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome	2007
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anti-cancer drugs, 2007, Volume: 18, Issue:9 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography	2007
Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:9 Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Female; Humans; Leg; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Vasculitis, Leukocytoclastic, Cutaneous	2007
Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer research, 2007, Sep-15, Volume: 67, Issue:18 Topics: Apoptosis; Cadherins; Cell Line, Tumor; Cell Movement; Dipeptides; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Silencing; Heparin-binding EGF-like Growth Factor; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Matrix Metalloproteinases; Pancreatic Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Transfection; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1	2007
Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-20, Volume: 25, Issue:27 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Research Design; Vascular Endothelial Growth Factor A	2007
Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-01, Volume: 25, Issue:28 Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quality-Adjusted Life Years; Quinazolines; Survival Analysis; United States	2007
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Quinazolines; Salvage Therapy; Survival Rate	2007
EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. The Journal of surgical research, 2007, Volume: 143, Issue:1 Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Cell Proliferation; Child, Preschool; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction	2007
Finding clinical meaning in cancer data. Journal of the National Cancer Institute, 2007, Dec-19, Volume: 99, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Evidence-Based Medicine; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sample Size; Survival Analysis	2007
Erlotinib in pancreatic cancer: are tumor cells the (only) target? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Dec-20, Volume: 25, Issue:36 Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Quinazolines	2007
Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochemical pharmacology, 2008, Mar-01, Volume: 75, Issue:5 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2008
Tumor resensitization to erlotinib following brief substitution of cetuximab. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2008
Erlotinib-induced episcleritis in a patient with pancreatic cancer. JOP : Journal of the pancreas, 2008, Mar-08, Volume: 9, Issue:2 Topics: Carcinoma; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Scleritis	2008
Erlotinib: new indication. Metastatic cancer of the pancreas: palliative care is still the best option. Prescrire international, 2008, Volume: 17, Issue:93 Topics: Drug Approval; Europe; Humans; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic	2008
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer research, 2008, Apr-15, Volume: 68, Issue:8 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Quinazolines; Transplantation, Heterologous	2008
Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clinical therapeutics, 2008, Volume: 30, Issue:4 Topics: Aged; Budgets; Deoxycytidine; Drug Costs; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Models, Economic; Neoplasm Staging; Outcome Assessment, Health Care; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Severity of Illness Index; Survival Rate; United States	2008
Phorbol ester reduces phosphorylation of epidermal growth factor receptor in pancreatic cancer cells by activation of a tyrosine phosphatase. Biochemical and biophysical research communications, 1999, Nov-30, Volume: 265, Issue:3 Topics: Cell Membrane; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Humans; Kinetics; Organometallic Compounds; Pancreatic Neoplasms; Phenanthrolines; Phosphorylation; Protein Tyrosine Phosphatases; Quinazolines; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Tyrphostins	1999
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer research, 2000, Nov-01, Volume: 60, Issue:21 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transport Proteins; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; Purine Nucleosides; Quinazolines; Thiophenes; Tumor Cells, Cultured; Urinary Bladder Neoplasms	2000
Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. British journal of cancer, 2001, Apr-06, Volume: 84, Issue:7 Topics: Cell Division; Culture Media, Serum-Free; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Flavonoids; Gastrin-Releasing Peptide; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor I; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Quinazolines; Substrate Specificity; Transcription Factor AP-1; Tumor Cells, Cultured; Tyrphostins	2001
ZD-1839 (AstraZeneca). Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:3 Topics: Anemia; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Diarrhea; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Tolerance; Drugs, Investigational; Economics, Pharmaceutical; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nausea; Pancreatic Neoplasms; Quinazolines; Tumor Cells, Cultured	2001
Activity of batracylin (NSC-320846) against solid tumors of mice. Investigational new drugs, 1989, Volume: 7, Issue:4 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Intraductal, Noninfiltrating; Cell Survival; Cells, Cultured; Colonic Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Pancreatic Neoplasms; Quinazolines; Tumor Cells, Cultured	1989